相关实验视频

Updated: Jun 9, 2025

Reduced Procedure Time and Variability with Active Esophageal Cooling During Radiofrequency Ablation for Atrial Fibrillation

Reduced Procedure Time and Variability with Active Esophageal Cooling During Radiofrequency Ablation for Atrial Fibrillation

Published on: August 25, 2022

在患有心房动的患者中,消化诱导的巴罗受体反射修饰和程序疗效之间的关联

Anna Zuk¹, Roman Piotrowski¹, Agnieszka Sikorska¹

¹Department of Cardiology, Centre of Postgraduate Medical Education, Grochowski Hospital, Warsaw, Poland.

Frontiers in cardiovascular medicine

|October 29, 2024

概括

对心房动 (AF) 的导管切除减少了巴罗受体 (BR) 功能,特别是在冷气球 (CB) 能量方面. 这种减少与手术后的AF复发率没有相关性.

科学领域:

心脏病学心脏病学
电子生理学电子生理学
自主神经系统研究自主神经系统研究

背景情况:

自主神经系统 (ANS) 显著影响心房动 (AF).
对AF的导管切除 (CA) 影响ANS,包括巴罗受体 (BR) 功能.
关于射频 (RF) 与冷却气球 (CB) 除能量如何影响BR功能和AF复发的知识有限.

研究的目的:

为了评估CA对AF关于BR功能修改的1年有效性.
为了比较RF与CB消光能对BR功能和AF结果的影响.

主要方法:

78名患有偏发性AF的患者首次接受了CA (39 RF, 39 CB).
非侵入性倾斜测试评估了CA前后的BR功能 (BREC,BRS,BEI).
一年后的随访包括门诊和霍尔特心电图;通过AFSS评估生活质量.

主要成果:

在1年内,CB (88.6%) 和RF (76.5%) 组的CA疗效相似.
在两组中,BR功能在CA后下降,CB组的下降明显更大.
BR参数的变化与切除反应无关;AF症状在两组中都有相似的改善.

结论:

对AF的导管切除显著降低了BR功能,特别是在冷却气球能量.
在CA诱导的BR参数变化和废除结果之间没有发现相关性.
需要进一步的研究,以了解改变BR功能后消去的临床影响.

关键词:

剥离疗效的疗效剥离疗效心房动是心房动的一种.心房的症状心房的症状自主神经系统自主神经系统巴罗受体的反射反应

更多相关视频

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

Robotic Ablation of Atrial Fibrillation

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

相关概念视频

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...